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Background: Neuroblastoma tumour resection goal is maximal tumour removal. We hypothesise that combining surgery with
sustained, local doxorubicin application can control tumour growth.
Methods: We injected human neuroblastoma cells into immunocompromised mouse adrenal gland. When KELLY cell-induced
tumour volume was4300mm3, 80–90% of tumour was resected and treated as follows: instantaneous-release silk film with 100mg
doxorubicin (100IR), controlled-release film with 200 mg (200CR) over residual tumour bed; and 100 and 200mg intravenous
doxorubicin (100IV and 200IV). Tumour volume was measured and histology analysed.
Results: Orthotopic tumours formed with KELLY, SK-N-AS, IMR-32, SH-SY5Y cells. Tumours reached 1800±180mm3 after 28 days,
2200±290mm3 after 35 days, 1280±260mm3 after 63 days, and 1700±360mm3 after 84 days, respectively. At 3 days post KELLY
tumour resection, tumour volumes were similar across all groups (P¼ 0.6210). Tumour growth rate was similar in untreated vs
control film, 100IV vs 100IR, and 100IV vs 200IV. There was significant difference in 100IR vs 200CR (P¼ 0.0004) and 200IV vs 200CR
(P¼ 0.0003). Tumour growth with all doxorubicin groups was slower than that of control (P:o0.0001–0.0069). At the interface of the
200CR film and tumour, there was cellular necrosis, surrounded by apoptotic cells before reaching viable tumour cells.
Conclusions: Combining surgical resection and sustained local doxorubicin treatment is effective in tumour control.
Administering doxorubicin in a local, controlled manner is superior to giving an equivalent intravenous dose in tumour control.
Neuroblastoma is the most common extracranial solid tumour in
children (Brodeur, 2003; Maris et al, 2007), with a prevalence of 1
in 7000–10 000 live births. The tumour originates from the neural
crest and presents in various locations along the sympathetic
nervous system. It predominantly occurs in the abdomen,
especially in the adrenal medulla (50%), but also develops in the
chest (20%), neck (4%), or pelvis (2%). It is a highly aggressive
tumour, where 10% of the patients with localised disease at
diagnosis experience a relapse, and 20% of those tumours become
refractory to treatment. With current therapy, the 5-year overall
survival of patients diagnosed with metastatic disease remains poor
(Matthay et al, 1999; Perez et al, 2000).
The challenges of treating patients with high-risk neuroblastoma
are several. Between 20% and 30% of these tumours do not
respond completely to induction therapy (Shafford et al, 1984). For
those tumours that initially respond to chemotherapy, the tumour
recurs in 20–30% of the cases (Park et al, 2008). The chemotherapy
regimen includes agents such as doxorubicin, cyclophosphamide,
and etoposide that can render the patient with side effects such as
cardiomyopathy, haemorrhagic cystitis, and myelosuppression as
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well as secondary malignancy such as breast or thyroid cancer
(Rubino et al, 2003). Even after the toxic chemotherapeutic regimen,
locally advanced tumours still cannot be completely resected because
of adhesion to vital structures such as the renal vein or the superior
mesenteric artery. Therefore, complete resection needs to be balanced
by organ preservation (La Quaglia et al, 1994).
When surgeons are confronted with patients with ‘seemingly
unresectable’ tumour burden, is there a strategy that can make
resection or total gross resection possible? A series of surgical patients
have demonstrated that the probability of local progression was 50%
in unresected patients vs 10% in stage 4 patients undergoing gross
total resection (La Quaglia et al, 2004). Furthermore, the overall
survival rate in resected patients was 50% compared with 11% in
unresected patients. Gross total resection offered a survival benefit for
stage 4 patients. Therefore, it would be advantageous to develop
strategies that augment the surgeons’ ability to completely resect
tumours with large burdens. Even increasing the percentage of
tumour that can be safely removed without injuring or sacrificing vital
structures may give more favourable clinical outcomes.
Local delivery of chemotherapeutic agents may enhance the results
of tumour resection. Clinically, chemotherapeutic agents are
administered locally to some malignancies including intravesical
therapy for bladder cancer and hepatic arterial infusion therapy
for hepatocellular carcinoma (van der Meijden et al, 1992;
Tzoracoleftherakis et al, 1999). A very aggressive treatment option
for cancers that have spread to the intraperitoneal lining uses
perfusion to deliver heating chemotherapeutic agents throughout the
intraperitoneal cavity (intraperitoneal hyperthermic chemoperfusion)
after surgical removal of localised tumours (Ceelen et al, 2000).
Implantable, carmustine-releasing polymer wafers (GLIADEL,
Eisai Inc., Woodcliff Lake, NJ, USA) are used for high-grade
malignant glioma and recurrent glioblastoma multiforme post
resection (Brem et al, 1995; Westphal et al, 2006).
For many centuries, silk has been used as suture material because
of its unique physical properties and excellent biocompatibility. More
recently, silk-based surgical meshes (Allergan Inc., Irvine, CA, USA)
have been approved for use in humans. Current efforts are geared
towards using silk as a delivery vehicle of chemotherapy (Seib and
Kaplan, 2012; Seib et al, 2013a, b) as well as other molecules,
including adenosine, penicillin, and vaccines (Pritchard et al, 2010;
Zhang et al, 2012; Pritchard et al, 2013). Silk is easily formulated
into films, hydrogel, microparticles, nanoparticles, microneedles, or
combination materials that are also 100% degradable in vivo
(Rockwood et al, 2011; Tsioris et al, 2012; Seib and Kaplan, 2013;
Seib et al, 2013a). This structural versatility, paired with the aqueous
processing technology, provides an additional advantage when
applying these silk-based drug delivery platforms in the biological
environment. Furthermore, the drug release profile of the silk
biopolymer can be varied from immediate release to slow release over
months (Wang et al, 2007), allowing for tailored drug administration
schedule to suit individual clinical scenarios.
We hypothesise that the margins of surgical resection can be
safely extended by applying the chemotherapeutic agent to the
residual tumour bed, thus decreasing the tumour growth rate after
resection. In this report, we tested this hypothesis by first
establishing an orthotopic xenograft mouse model of neuroblas-
toma followed by surgical resection after the tumour volume
reached 4300mm3. We then applied doxorubicin locally by
utilising silk films as a drug delivery platform. The films were
engineered to achieve instantaneous release or an initial rapid
release followed by a sustained drug release.
MATERIALS AND METHODS
Cell culture. Four neuroblastoma cell lines with different genetic
makeup were used. Human neuroblastoma SK-N-AS cells
(American Type Culture Collection (ATCC, Manassas, VA,
USA)) were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, HyClone, Logan, UT, USA) supplemented with 10% fetal
bovine serum, 100 IUml 1 penicillin, 100 mgml 1 streptomycin,
and 0.1mM non-essential amino acids. Human neuroblastoma
IMR-32 cells (ATCC) were maintained in modified Eagle’s
medium (MEM, HyClone) supplemented with 10% fetal bovine
serum, 100 IUml 1 penicillin, and 100 mgml 1 streptomycin.
Human neuroblastoma SH-SY5Y cells (ATCC) were maintained in
1 : 1 mixture of MEM and F-12 media supplemented with 10% fetal
bovine serum, 100 IUml 1 penicillin, and 100 mgml 1 strepto-
mycin. Human neuroblastoma KELLY cells (Sigma-Aldrich,
St Louis, MO, USA) were maintained in RPMI-1640 (HyClone)
supplemented with 10% fetal bovine serum, 100 IUml 1
penicillin, 100 mgml 1 streptomycin, and 2mM glutamine. All
cells were maintained in a 5% CO2 atmosphere at 37 1C and
trypsin-passaged at 80% confluence.
Animal procedure. All mouse procedures were performed in
accordance with Tufts University’s recommendations for the care
and use of animals and were maintained and handled under
protocols approved by the Institutional Animal Care and Use
Committee. All procedures were performed with female NCr nude
mice or BALB/c mice (Taconic, Hudson, NY, USA) at 7 weeks of
age. Procedures and ultrasound measurements were performed
under general anaesthesia using isoflurane inhalation. At least five
animals were used for each experimental group unless otherwise
stated.
Creation of neuroblastoma tumours. A transverse incision was
made on the left flank. The abdominal viscera were retracted
medially and the retroperitoneal space was entered. The left
adrenal gland was located, and 2 ml of phosphate-buffered saline
(PBS) containing a predetermined cell number was injected into
the adrenal gland via a 30G needle. The abdominal viscera were
then returned into the abdominal cavity and the fascia and skin
layers closed. Tumour formation was followed by ultrasound
measurements, and the animals were killed when the tumour
volume exceeded 1000mm3. The tumours and organs were
removed and processed as detailed below. In addition, four
animals that had received 106 KELLY cells were killed at
postoperative day 3 (n¼ 2) and day 14 (n¼ 2).
Resection of neuroblastoma tumours and application of silk
films. For the tumour resection model, tumours formed by
injection of 106 KELLY cells were tracked by ultrasound. When
the tumour reachedB300mm3, surgical resection was performed.
Briefly, a transverse incision was made on the left flank. The
abdominal viscera were retracted medially and the retroperitoneal
space entered. The left kidney was first located, and the tumour
originating from the left adrenal gland identified. Using a
combination of scalpel and electrocautery, B80–90% of the
tumour volume was excised. Electrocautery and direct pressure
were used to maintain haemostasis of the residual tumour surface.
In the experimental groups, a single, sterile, doxorubicin-contain-
ing silk film was placed on the tumour resection bed and the fascia
and the skin were closed in separate layers. Instantly soluble or
controlled-release silk films contained a nominal doxorubicin
loading of 100 and 200 mg, respectively (denoted as 100IR and
200CR). The control groups consisted of surgical resection with no
treatment (untreated), control insoluble silk film (control film),
and tail vein injection of 100 mg doxorubicin (100IV) and 200 mg
doxorubicin (200IV) in 100 ml of saline solution. Tumour volume
was measured twice a week via ultrasound. Animals were killed
when the tumour volume exceeded 1000mm3. The tumours and
organs were processed as described below. Some animals that
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received tumour resection and 200CR films were killed at 1 h
(n¼ 2), 24 h (n¼ 2), and 72 h (n¼ 3) after implantation.
High-frequency ultrasound. The mouse was secured to the stage
in a prone position. Next, a VisualSonics Vevo 2100 Sonographic
probe (Toronto, ON, Canada) was applied to the left flank to locate
the left adrenal gland and the tumour. Serial cross-sectional images
(0.076mm between images) were taken. The tumour volume was
measured using the 3-D reconstruction tool (Vevo Software
v1.6.0).
Engineering of the silk films. Silk was isolated for Bombyx mori
cocoons as previously described (Seib and Kaplan, 2012). Briefly,
cocoons were boiled in 20mM sodium carbonate for 30min and
then washed with deionised water. The resulting fibres were air
dried and then dissolved in 9.3M lithium bromide at 60 1C for 4 h.
The solution was dialyzed (3.4 kDa MWCO, Piece, Rockford, IL,
USA) against deionised water for 2 days. To produce 100IR films,
385 ml of 2% w/v silk fibroin solution containing 865 mgml 1
doxorubicin-HCl (LC Laboratories, Woburn, MA, USA) was cast
on an 11mm  17mm polydimethylsiloxane mould. The solution
was allowed to air dry overnight. The resulting films were cut to
7mm  11mm, resulting in 100 mg doxorubicin-loaded, instantly
soluble silk films. To produce 200CR films, 436 ml of 2% silk fibroin
solution was cast on a 13mm  17mm PDMS mould and air
dried overnight. Then, 59 ml of 7mgml 1 doxorubicin was
pipetted onto the silk film and air dried overnight. The resulting
film was cut to 7mm  11mm and the silk was physically
crosslinked via water vapor annealing overnight at room
temperature following a previously published method (Seib and
Kaplan, 2012).
In vitro measurement of doxorubicin release from silk film.
Doxorubicin loading and release was determined by light
absorbance at 482 nm using a SpectraMax M2 spectrophotometer
(Molecular Devices, Sunnyvale, CA, USA). For quantification of
soluble film loading, films were dissolved in PBS and absorbance
values converted to concentration via a standard curve made in
PBS. For quantification of insoluble film loading, films were
dissolved using 100 ml 9.3M lithium bromide at 60 1C for
30–60min. The resulting solution was diluted with 900 ml PBS.
Absorbance values were converted to concentration via a standard
curve made in 0.93M lithium bromide/PBS solution. In vitro
release curves were generated via release in PBS. Briefly, samples
were incubated in 1ml of PBS under static conditions. At each time
point, the entire volume of PBS was removed and replaced with
fresh PBS to ensure sink conditions.
In vivo measurement of doxorubicin release from silk film.
After the female BALB/c mouse was anaesthetised with isoflurane
inhalation, a transverse incision was made on the left flank. The
abdominal viscera were retracted medially and the retroperitoneal
space was entered. The left kidney and adrenal were identified and
a 200CR film placed over them. The fascia and skin were closed in
separate layers. Animals treated in this manner were randomly
enrolled into one of the following groups, with each group
consisted of five animals killed according to the prescribed time
points: postoperative days 1, 2, 3, 7, 10, 14, 21, and 28. The films
were retrieved after killing of animal. The remaining doxorubicin
was quantified to generate the in vivo release profile as described
above for loading of insoluble films. The 28- day implanted control
films were used as background controls.
Morphologic examination. After the animals were killed, the
tumours were removed, fixed in 10% buffered formalin, serially
dehydrated and embedded in paraffin. Then, 5 mm thick sections
were collected onto glass slides. Sections were stained with
haematoxylin and eosin. To visualise proliferative cells, sections
were stained using an anti-Ki67 antibody. To visualise apoptotic
cells, sections were stained using the TUNEL assay (TACS-XL
DAB In Situ Apoptosis Detection Kit, R&D Systems, Minneapolis,
MN, USA). All sections were subjected to morphological
examination by light microscopy.
Statistics. All animals that underwent resection and subsequent
treatments were included in the statistical analysis at specific time
points; all animals within a treatment group were excluded from
subsequent tumour measures, as a group, when all animals within
the group had reached the predetermined maximum tumour size
range.
The analysis objective was to examine changes in tumour
volume over time and compare tumour growth rates across
experimental groups. As an initial step, ANOVA was used to
compare the first measure of tumour volume (at postoperative day 3)
across the six experimental groups. To estimate and compare
tumour growth rates, we used a random effects model in which a
different intercept and slope for each experimental group was
estimated. This model does not require equal lengths of follow-up
time to measure tumour growth rates. The model intercept for
each treatment group represents the mean tumour volume at
postoperative day 3, and the slope for each treatment group
represents the change in tumour volume over time. The untreated
group was used as the reference group in the model. Additional
group comparisons were evaluated using prespecified two-group
contrasts. Because of multiple testing, statistical significance was
determined after controlling for the false discovery rate (Benjamini
and Hochberg, 1995). Data for release studies and tumour volumes
are presented as average±s.d.
RESULTS
Tumour model establishment. Evaluation of the tumour model
was performed using high-frequency ultrasound imaging. All
tumour volumes were measured noninvasively with high-fre-
quency ultrasound by taking serial cross-sections of the adrenal
gland or tumour (Figure 1A). Three-dimensional reconstructions
were then created from these cross-sections and measured
manually to obtain the volumetric measurements (Figure 1B and C).
All four neuroblastoma cell lines were capable of establishing
neuroblastoma tumour with a 106 cell injection into the adrenal
gland of immunocompromised mice. The KELLY cells had the
fastest rate of growth, reaching an average of 1800±180mm3 after
28 days (Figure 2A). The SK-N-AS cells had a slightly slower
growth rate, reaching 2200±290mm3 after 35 days (Figure 2A).
The IMR-32 cells required 63 days to reach 1280±260mm3
(Figure 2A). SH-SY5Y had the slowest growth rate, reaching
1700±360mm3 only after 84 days (Figure 2A).
Injection of 104 KELLY cells took longer (1940±240mm3 after
56 days) (Figure 2B) to establish tumours compared with 106
KELLY cells (1800±180mm3 after 28 days). Injection of 103
KELLY cells did not establish a tumour after 56 days (Figure 2B),
and histological examination of these adrenal glands showed no
tumour cell engraftment (data not shown). At 3 days after injecting
106 KELLY cells, there was extensive ischaemia within the adrenal
gland and no detectable tumour engraftment (Figure 1D). The
tumour was observed in the adrenal gland at 14 days (Figure 1E).
Controlled release of doxorubicin from silk films. Doxorubicin
release from 200CR films was monitored in vitro and in vivo.
During the in vitro release, B100 mg of doxorubicin was released
immediately. Over the following 30 days, B40 mg of doxorubicin
was released (Figure 3). The slow release portion of the release
curve is comparable to previous literature (Seib and Kaplan, 2012).
The 200CR films were designed to release 100 mg doxorubicin
initially to elicit a rapid tumour response followed by a sustained
release to facilitate slowing of tumour regrowth. In vivo, B100 mg
BRITISH JOURNAL OF CANCER Surgery with doxorubicin films in treating neuroblastoma
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of doxorubicin was also released immediately followed by slow
release of 80 mg doxorubicin over the following 30 days (Figure 3).
The major difference between the in vitro and in vivo release was
observed within the first 4 days. Overlaying the release curves after
the initial 4 days showed no significant differences in the release
kinetics (data not shown).
Altered tumour growth kinetics upon implantation of doxor-
ubicin-loaded silk films. For treatment studies, tumours were
formed using 106 KELLY cells injected into the left adrenal gland.
Once the tumour volume reached 4300mm3, the animal under-
went an 80–90% tumour resection before it was enrolled in one of
the following six experimental groups: (1) untreated, (2) control
silk film, (3) 100IV, (4) 200IV, (5) 100IR, and (6) 200CR.
Ultrasound measurements of the tumour volume began 3 days
after tumour resection. At day 3, the mean tumour volume ranged
from 22.3 to 42.1mm3 (Figure 4) with no significant differences
among the six groups (ANOVA, P¼ 0.6210). Untreated tumours
reached a volume of 1102.3±265.1mm3 after 17 days that was
Kid T
Figure 1. Ultrasound and histological imaging (haematoxylin and eosin stained) of 106 KELLY cell-induced tumour and the associated adrenal
gland. (A) Ultrasound image of the cross-section of the adrenal gland. The hyperechoic centre denotes the medulla. (B) Three-dimensional
reconstruction of the adrenal gland, from which the volume measurement was made. (C) A cross-sectional view of the tumour that was adjacent to
the kidney. Kid¼ kidney; T¼ tumour. (D) The adrenal gland with extensive necrosis 3 days after 106 KELLY cells were injected (100). (E) The
adrenal gland with intramedullary neuroblastoma 14 days after 106 KELLY cells were injected ( 100; arrow). The inset shows neuroblastoma cells
at a higher power (1000, oil).
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Figure 2. Tumour growth over time quantified by image analysis of
ultrasound imaging. (A) Tumour volume at predetermined time points
after injections with 106 KELLY, SK-N-AS, IMR-32, and SH-SY5Y cells.
(B) Tumour volume at various time points after injections with 104 and
103 KELLY cells (n¼ 5).
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Figure 3. Cumulative doxorubicin released over time in the in vitro
and in vivo setting. For in vitro release studies, doxorubicin is
quantified in PBS. For the in vivo release studies, the remaining
doxorubicin in the film is quantified and subtracted from the average
initial loading (in vitro n¼ 3, in vivo n¼ 3–5).
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comparable to control film-treated tumours of 1419.6±170.2mm3
(P¼ 0.0764 for growth rate comparison; Figure 5A). All
doxorubicin-containing groups had significantly slower tumour
growth (P value ranged from o0.0001 to 0.0069) compared with
the control film group (Figures 5A–D). In animals that received
100IV or 200IV, the tumour volume reached 1018.3±408.2mm3
after 21 days and 1051.3±422.5mm3 after 28 days, respectively
(growth rate comparison P¼ 0.0465, but not statistically significant
after controlling for the false discovery rate; Figure 5A). In
animals that received 100IR films, the tumour volume reached
1004.0±201.9mm3 after 28 days, significantly faster tumour growth
compared with 200CR film-treated tumours (928.7±389.6mm3 after
49 days, P¼ 0.0004; Figure 5B). The 100IR film treatment resulted
in a similar tumour growth rate compared with 100IV treatment
(P¼ 0.0487, not statistically significant after controlling for
the false discovery rate; Figure 5C). However, treatment with
200CR films significantly decreased the tumour growth rate
compared with 200IV injection (P¼ 0.0003; Figure 5D). The
200CR film treatment outperformed all of the other groups
studied.
Histological assessment of tumours. Animals that received
200CR film treatment after resection of the original tumour were
killed at day 49. Histological assessment of the tumours revealed
that there was a zone of cellular necrosis immediately adjacent to
the film (Figure 6A). This zone of cellular necrosis was surrounded
by proliferative tumour cells evident by positively staining for Ki67
(Figure 6C). At the interface between the viable tumour cells and
the zone of cellular necrosis, there appeared to be a transition zone
of apoptotic cells (Figure 6B).
To further characterise the pathological changes associated with
200CR films, a short-term time course experiment was performed.
Animals that underwent resection of the original adrenal tumour
were either treated with control films, 200CR films, or left
untreated. After the aforementioned treatments, the animals were
killed at 1, 24, and 72 h. Untreated tumours or control film treated
tumours showed predominantly viable tumour cells at 1 h (data not
shown), 24 h (Figure 7A and B), and 72 h (Figure 7D and E).
Tumours treated with 200CR film had necrotic cells adjacent to the
film starting at 24 h (Figure 7C) that persisted through 72 h
(Figure 7F).
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vs 100IR, 200CR vs 200IV; Po0.0001: 100IR vs control film, 200CR vs control film, 200IV vs control film).
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DISCUSSION
We have successfully demonstrated that four different neuroblas-
toma cell lines, KELLY, SK-N-AS, IMR-32, and SH-SY5Y, are
capable of establishing adrenal tumours in an orthotopic xenograft
injection mouse model. These four cell lines possess different
genetic characteristics in terms of the MYCN amplification status
and anaplastic lymphoma kinase (ALK) receptor status (Table 1).
Morphological examination of the adrenal gland after the injection
demonstrated initial extensive necrosis. The established adrenal
tumour was composed of small cells, frequently in association with
necrosis, and was showing brisk mitotic and apoptotic activity as
seen in neuroblastoma.
No macroscopic or microscopic metastases were noted in our
model as compared with the other published reports of orthotopic
xenograft neuroblastoma animal models (Henriksson et al, 2004;
Fuchs et al, 2009). One possible explanation is because of the use of
NCr nude mice as opposed to SCID mice that are more permissive
to metastasis (Mueller and Reisfeld, 1991). Another potential
reason relates to the technique used for tumour injection. In the
orthotopic injection neuroblastoma model reported by Henriksson
et al (2004), a 10 ml injection volume was used. As the mouse
adrenal gland is only B3mm3, most of the tumour cells injected
spill into the abdominal cavity as described by the authors,
inoculating other tissues in the vicinity. In our model, we have
concentrated the tumour cells requiring only a 2 ml injection
volume. Furthermore, a needle with a shortened bevel was used so
that the entire needle opening was within the adrenal gland during
injection.
In our model, we used high-frequency ultrasound to perform
repeat, longitudinal, and noninvasive determinations of the tumour
volume. Using this fast and accurate methodology to monitor
tumour growth parameters, Teitz et al (2011) compared the use of
ultrasound with that of bioluminescence and magnetic resonance
imaging (MRI) for assessing tumour volume in an orthotopic
xenograft neuroblastoma model. They found excellent volume
measurement correlation between the different modalities. The
MRI provided superior detail in tumour origin and composition
but at a higher cost and much longer imaging time. The
combination of a reliable, reproducible, and efficient orthotopic
injection model with an accurate, noninvasive volume measure-
ment system creates an ideal platform for preclinical testing of
therapeutic agents.
In our work, there was a minimum cell number required
to establish an orthotopic neuroblastoma xenograft. With a
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Figure 6. Histological analysis of 200CR film-treated tumour at day 49 post resection. (A) Haematoxylin and eosin staining of the tumour (40;
*denotes viable tumour) At the silk film/tumour interface, a zone of cellular necrosis can be observed (small arrowhead denotes film). Ki67 staining
of the tumour (B,  200; C, 200). At the interface between the viable tumour cells and the zone of cellular necrosis, there appeared to be a
transition zone of apoptotic cells (B) (large arrowhead). Viable tumour cells surrounded the transition zone (C).
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Figure 7. Haematoxylin and eosin staining of tumour bed at 1, 24 and 72h post resection. Viable cells can be seen in the tumour bed at 24 and
72h post resection that were untreated (A and D) and control film treated (B and E). However, 200CR film-treated tumour beds exhibited cellular
necrosis at 24 h (C) and 72 h (F) post excision. Arrow denotes the silk film (A–F, 100).
Table 1. Genetic characterisations of the neuroblastoma cell lines
Cell line KELLY IMR-32 SH-SY5Y SK-N-AS
MYCN status Amplified Amplified Nonamplified Nonamplified
ALK mutation Yes No Yes No
Abbreviation: ALK¼ anaplastic lymphoma kinase.
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decreasing number of cells injected, the time required to establish
the tumour is increased. No tumour was observed with 103 KELLY
cells injected. Histological examinations of these adrenal glands did
not demonstrate tumour formation. These finding with the KELLY
cell line suggest that certain percentage of these cells possess a
tumour-initiating property, and a threshold of cell number needs
to be achieved to ensure these cells are present. The presence of
tumour-initiating cells have been demonstrated in human tumour
samples obtained from pre- and post-treatment neuroblastoma
tumours from the bone marrow of patients who had relapsed after
multiple courses of chemotherapy and from the bone marrow of
patients in remission (Hansford et al, 2007).
Frequently, surgery is an integral component of clinical cancer
care. The ability to closely model the behaviour of tumours in their
orthotopic location after undergoing surgical resection, mimicking
the clinical scenario, can be key to improving the effectiveness of
surgical therapy. Our model meets this need by establishing a
sizable neuroblastoma tumour in the adrenal gland as well as
allowing for surgical resection of 80–90% of the tumour, similar to
the frequently encountered clinical scenarios. Davis et al (1990)
combined neuroblastoma tumour resection with intraoperative
photodynamic therapy to demonstrate the reduction in the rate of
tumour recurrence. However, this report could not accurately
quantify the amount of tumour before or after resection. Pastorino
et al (2008) utilised surgical resection in their orthotopic
neuroblastoma mouse model and quantified the perioperative
tumour size with a luciferase/bioluminescence system. Despite
being a frequently used research tool, the bioluminescence system
is not a clinical option. The ultrasound system we used for tumour
volume measurement is more readily translated clinically.
The animals were able to tolerate the stress of the surgical
tumour resection. The haemostatic manoeuvres such as direct
pressure and electrocautery were sufficient to ensure a safe
procedure. We also found that breaking the tumour capsule and
spilling tumour cells into the abdominal cavity did not result in
dissemination of tumour within the abdominal cavity. In fact, the
residual tumour remained at the original tumour bed serving as the
focus of additional tumour growth. In addition, we did not observe
any tissue ischaemia or organ loss in our series.
We found that the tumour growth rate was not significantly
different between untreated and control film-treated residual
tumour beds. Therefore, the presence of silk films alone does not
alter tumour regrowth. There was a substantial difference between
animals that received an intravenous bolus of either 100 or 200 mg
of doxorubicin compared with those with control films, with the
better tumour response for the latter treatment group. Variable
blood supply to the residual tumour bed could have led to a
variable amount of doxorubicin delivered, thus resulting in
different degrees of drug exposure between the animals receiving
different intravenous doses (el-Kareh and Secomb, 1997).
Treating the residual tumour with one application of 100 mg
doxorubicin via intravenous injection or instantaneous released
film placement resulted in similar tumour growth rate. However,
applying doxorubicin locally vs systemically could lead to fewer
systemic side effects such as cardiomyopathy. Local application of
chemotherapeutic agents may be a less toxic strategy for the overall
tumour treatment protocol and warrants further investigation.
Alternatively, when the dosage of the doxorubicin was doubled
in the locally delivered silk films, the tumour growth rate was
slowed significantly. The effect of doxorubicin on slowing tumour
growth appeared to be more effective when the 200CR film was
utilised compared with 200IV injections. The controlled-release
nature of the silk platform clearly demonstrated the advantage of
applying small doses of doxorubicin over time as opposed to one
bolus dose. Our local delivery system allows for complete
availability of the drug to the tumour, whereas in IV-administered
drug, pharmacokinetic/pharmacodynamics dictate the bioavailability
to the tumour. Coupling the local delivery with sustained release
resulted in superior slowing of tumour growth because of the
constant administration of drug directly to the tumour. There are
many other factors that may have played a role in the effects seen
with the local, sustained-release films. The controlled release of
doxorubicin may create an environment that continually elimi-
nated cancer stem cells (Reya et al, 2001) or maintained the total
tumour cells just below a critical number to spur exponential
tumour growth, as observed when too few cells were injected for
tumour formation. Furthermore, the tumour microenvironment
may have been altered by doxorubicin (Kang et al, 2013).
Doxorubicin has been shown to induce apoptosis through the
CD95 system (Fulda et al, 1997). Histological examination of the
tumours revealed that tumour cell death was the result of local effect
rather than effects of systemic doxorubicin absorption. This is evident
by cell death radiating away from the 200CR film through parts of the
tumour. Our histological observation suggested that doxorubicin
contained within the controlled-release silk film was diffused across
the tumour, resulting in apoptosis and subsequent necrosis.
Extending the findings of our work to the clinical setting, there
are some issues to be considered. First, the tumour-bearing animals
are cytotoxic naive before resection and application of the
doxorubicin-loaded silk films. Clinically, patients with advanced-
stage neuroblastoma would have previously been exposed to
cytotoxic therapy before surgery (Maris, 2010). Previous exposure
to doxorubicin could result in the tumour harbouring doxorubicin-
resistant cells (Maris, 2010), rendering the doxorubicin-loaded silk
film less effective. As a higher effective doxorubicin dose can be
delivered locally compared with that delivered systemically, we
speculate that the small amount of tumour remaining after
resection, possibly containing doxorubicin-resistant cells, can be
overcome by sustained local application of doxorubicin. Second,
despite the large size of the tumour described in our model, it is
localised to the adrenal gland. However, locally advanced
neuroblastoma tumours in patients frequently involve multiple
sites (Maris, 2010). A potential solution will be to apply individual
drug-loaded films at multiple sites. This approach will be
ineffective if the tumour is already systemically disseminated.
In conclusion, we have shown that combining surgical resection
with a doxorubicin-loaded, sustained-release silk film system is an
effective strategy in decreasing neuroblastoma tumour growth.
Future studies in characterising the local/systemic distribution of
the drug as well as potential systemic toxicity will be essential in
considering this strategy in a clinical setting.
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